Congress Should Not Impose Foreign Price Controls On Innovative Drugs
By: bitcoin ethereum news|2025/05/04 09:00:01
0
Share
VALUE and PRICE balancing Simple and neat solutions are alluring but often wrong. A case in point is President Trump’s proposal to adopt a most favored nation (MFN) policy. The MFN sets Medicaid’s price for a drug at the lowest price charged in other developed countries each of which has price controls on drugs. If implemented, this policy will make a bad situation much worse. The logic for implementing the MFN is simple – if patients in the U.K. or Canada are paying less money for a drug, then so should patients in the U.S. But the prices for innovative drugs in many OECD countries are only lower because these nations impose strict price controls, which always come with a high cost. To start with, price controls diminish drug availability. Thanks to price controls, patients in the other major industrialized countries (OECD) have access to only 29% of new medicines while patients in the U.S. have access to 85%. Even worse, patients in Canada and the U.K. can wait years for access to the latest treatments in some cases, and at any given time in Canada, there is a shortage of between 1,500 and 2,000 drugs. In those cases where the drugs are available in foreign nations, adopting the MFN policy outsources U.S. health policy to these countries. The U.S. should not impose price controls, but if it does, drug pricing decisions should not be outsourced to the EU, UK, or Canada. Adopting the MFN will also harm innovation. Developing a new drug takes a lot of time and money. On average, developing one innovative drug takes over $2.9 billion (including post-marketing expenditure) and between 10 and 15 years. It is also a risky endeavor. Approximately 9 out of every 10 drugs that reach the clinical trial stage will ultimately fail. Drug price controls make it harder for innovative firms to cover their capital costs, which reduces the amount of money spent on new innovations. A University of Chicago Issue Brief by Philipson and Durie found “that a 1 percent reduction in revenue leads to a 1.5 percent reduction in R&D activity.” The consequences from disincentivizing innovation would hit the U.S. economy hard. According to the latest industry economic impact report, the biotechnology industry directly contributed $1.4 trillion to the economy in 2023 (around 6.8% of the private sector GDP), supported nearly 2.3 million jobs, and paid hundreds of billions of dollars in taxes to the federal government. Perhaps even more important, the lost innovation from price controls harms patients currently living with diseases that have inadequate or no treatment options. If price controls are adopted in the U.S., then patients living with Alzheimer’s disease, pancreatic cancer, or muscular dystrophy may end up waiting in vain for efficacious treatments. Ultimately, the problem is that foreign governments are imposing price controls on drugs. The result is that patients across the globe benefit from American pharmaceutical innovation without paying their fair share of the innovation’s costs. The best way to address this problem is to defend the intellectual property of U.S. firms in trade negotiations. Executing on this goal could include appointing a pharmaceutical trade negotiator at USTR to defend American companies’ interests. Successfully concluding these negotiations is a long-term project, however. There are beneficial reforms that Congress can implement now that will promote greater drug availability in the meantime. These reforms should address the many inefficiencies that plague the U.S. drug market. For instance, more than half of the revenues from drug sales goes to hospitals, pharmacies, and other middlemen thanks to errant policies. These errant policies include the 340B drug discount program, which now has the contradictory impact of raising overall drug prices. Reforms should demand greater transparency in the program and mandate 340B only serves its intended population. These changes will improve 340B’s effectiveness while relieving the inflationary price pressures created by the program. Another necessary reform would address the current opaque drug pricing system that is empowering pharmacy benefit managers (PBMs) to the detriment of patients. Thanks to the system’s misaligned incentives, costs are being inequitably shifted to patients. Worsening the problem, the system often encourages the use of more expensive medicines rather than lower cost alternatives. Reining in PBMs will improve the drug market’s incentives resulting in lower out-of-pocket costs for patients without diminishing the incentives for innovation. The FDA approval process is also slow and overly burdensome. Reforming this process can lower the cost of developing new treatments while expediting their availability to patients. The goal of U.S. drug policy should be to promote the dual goals of innovation and broad-based affordability. The MFN policy adopts foreign imposed price controls that will discourage innovation and reduce patients access to medicines. While spending on medicine may go down, total healthcare spending is likely to increase as patients wind up requiring more expensive surgeries and hospital stays. Promoting more affordable drugs is not simple. It requires the hard work of understanding what is driving the problem and implementing policies that directly fix them. The MFN is a shortcut that patients will quickly come to regret. Source: https://www.forbes.com/sites/waynewinegarden/2025/05/03/congress-should-not-impose-foreign-price-controls-on-innovative-drugs/
You may also like

Circle has been on the market for 270 days, working hard to shed the stablecoin label
Striving to reaffirm its status as a tech company while in regulatory limbo.

Interpreting Stripe’s 2025 Letter: Despite the Crypto Winter, It’s Still Stablecoin Season
Bridge's Quadruple Growth, Privy's Billion-Level Wallet, Tempo Testnet Landing, and Stablecoin Penetration in the B2B Space are all silently reshaping the global economic infrastructure.

After Jane Street Halts 10% Sell-Off, BTC Sees Strong Rebound
「BTC Should Be Worth At Least $150,000」

Myanmar in Turmoil: The Sanctity of the Dollar, Trapped Youth, and the Underground Financial System
A Glimpse of Myanmar and Its Underground Financial Market.

Wall Street's Most Mysterious Money-Making Machine, Crashing Bitcoin Price at 10 a.m. Sharp Every Day
Jane Street's reputation has continued to suffer in recent years

Key Market Information Discrepancy on February 26th - A Must-Read! | Alpha Morning Report
1. Top News: Major Cryptocurrencies, Including Bitcoin, Surge; Jane Street Halts "10 AM Dump" After Lawsuit
2. Token Unlock: $MIRA, $SAHARA, $HUMA, $BLAST, $ALOT

How was the Backpack staking token swap established?
Backpack is taking a path of unvalidated transactions, requiring a delicate balance between regulators, equity holders, and token stakers.

Can You Still Launch a VC Firm Today?
Put Your Reputation on the Line, Find a Clear Edge, Win a Few Key Trades, and Stay in It for the Long Haul

Claude Cowork Adds Scheduled Task, Jane Street Incident Continues to Stir, What's the Overseas Crypto Community Talking About Today?
What Was Trending for Foreigners in the Last 24 Hours?

Leveraging $6,000 to Move a $200M Market Cap? How Polymarket Creates an "Insider Trading Illusion"
After a large bet on Meteora on Polymarket, the price of MET rose instead of falling within an hour.
WEEX AI Hackathon: $8B Traded, Real AI Strategies Proven
How profitable is AI trading in real crypto markets? WEEX's $1.88M global AI hackathon reveals $8B volume, 227% ROI, API strategy data, and why only 8 of 37 traders made profit.

Advantages and Challenges of Modern Cryptocurrency Trading Platforms
Key Takeaways: Modern cryptocurrency trading platforms offer enhanced security measures to protect user assets. User-friendly interfaces and comprehensive…

Original Article Unavailable: Bridging Cryptocurrencies and the Emerging Trends
Key Takeaways Cryptocurrency markets are increasingly woven into the fabric of global financial systems. With advancements in blockchain…

Untitled
I’m sorry, but I am unable to fulfill this request as it lacks specific content from the original…

The one who bought the Meta stablecoin Diem back in the day is a good friend of SBF.
The original idea was to combine a bank-licensed compliant entity with an underlying clearing network built over three years by a Silicon Valley giant, to enable seamless payments for everything you can imagine

February 25th Market Key Insights, How Much Did You Miss Out?
1. On-Chain Funds: $32M inflow to Ethereum this week; $54.9M outflow from Arbitrum
2. Largest Price Swings: $SN115, $RAVE
3. Top News: Tonight's Circle and NVIDIA earnings reports, AI narrative's impact on crypto market sentiment under scrutiny

Dragonfly Partner Haseeb Conversation: The AI Apocalypse is Far Away; Smart Contracts are Machine-Destined Law
In the world of crypto, the first lesson you learn is the importance of "HODLing" on.

IOSG: DeFi Upward, User Downward; Curator's New Paradigm of CeDeFi
As DeFi matures and grows more complex, the Curator is becoming a key intermediary connecting risk and users.
Circle has been on the market for 270 days, working hard to shed the stablecoin label
Striving to reaffirm its status as a tech company while in regulatory limbo.
Interpreting Stripe’s 2025 Letter: Despite the Crypto Winter, It’s Still Stablecoin Season
Bridge's Quadruple Growth, Privy's Billion-Level Wallet, Tempo Testnet Landing, and Stablecoin Penetration in the B2B Space are all silently reshaping the global economic infrastructure.
After Jane Street Halts 10% Sell-Off, BTC Sees Strong Rebound
「BTC Should Be Worth At Least $150,000」
Myanmar in Turmoil: The Sanctity of the Dollar, Trapped Youth, and the Underground Financial System
A Glimpse of Myanmar and Its Underground Financial Market.
Wall Street's Most Mysterious Money-Making Machine, Crashing Bitcoin Price at 10 a.m. Sharp Every Day
Jane Street's reputation has continued to suffer in recent years
Key Market Information Discrepancy on February 26th - A Must-Read! | Alpha Morning Report
1. Top News: Major Cryptocurrencies, Including Bitcoin, Surge; Jane Street Halts "10 AM Dump" After Lawsuit
2. Token Unlock: $MIRA, $SAHARA, $HUMA, $BLAST, $ALOT